Publication: Angiopoietin as a novel prognostic marker in kidney disease
dc.contributor.coauthor | Gaipov, Abduzhappar | |
dc.contributor.coauthor | Magagnoli, Lorenza | |
dc.contributor.coauthor | Ciceri, Paola | |
dc.contributor.coauthor | Cozzolino, Mario | |
dc.contributor.kuauthor | Yıldız, Abdullah Burak | |
dc.contributor.kuauthor | Çöpür, Sidar | |
dc.contributor.kuauthor | Tanrıöver, Cem | |
dc.contributor.kuauthor | Yavuz, Furkan | |
dc.contributor.kuauthor | Vehbi, Sezan | |
dc.contributor.kuauthor | Kanbay, Mehmet | |
dc.contributor.schoolcollegeinstitute | School of Medicine | |
dc.date.accessioned | 2024-12-29T09:36:39Z | |
dc.date.issued | 2024 | |
dc.description.abstract | Introduction: Renal injury is among the leading causes of morbidity and mortality; however, there are no reliable indicators for determining the likelihood of developing chronic kidney disease (CKD), CKD progression, or AKI events. Vascular growth factors called angiopoietins have a role in endothelial function, vascular remodeling, tissue stabilization, and inflammation and have been implicated as prognostic and predictive markers in AKI. Methods: Although the exact mechanism of the relationship between kidney injury and angiopoietins is unknown, this review demonstrates that AKI patients have higher angiopoietin-2 levels and that higher angiopoietin-1 to angiopoietin-2 ratio may potentially be linked with a reduced risk of the CKD progression. Results: This review therefore emphasizes the importance of angiopoietin-2 and proposes that it could be an important predictor of AKI in clinical settings. Conclusion: There is a need for further large-scale randomized clinical trials in order to have a better understanding of the significance of angiopoietin-2 and for the determination of its potential clinical implications. | |
dc.description.indexedby | WoS | |
dc.description.indexedby | Scopus | |
dc.description.indexedby | PubMed | |
dc.description.issue | 6 | |
dc.description.publisherscope | International | |
dc.description.volume | 53 | |
dc.identifier.doi | 10.1159/000536439 | |
dc.identifier.eissn | 1421-9735 | |
dc.identifier.issn | 0253-5068 | |
dc.identifier.quartile | Q2 | |
dc.identifier.scopus | 2-s2.0-85194489018 | |
dc.identifier.uri | https://doi.org/10.1159/000536439 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14288/22111 | |
dc.identifier.wos | 1243653000003 | |
dc.keywords | Angiopoietin | |
dc.keywords | Acute kidney injury | |
dc.keywords | Kidney disease progression | |
dc.keywords | Chronic kidney disease | |
dc.language | en | |
dc.publisher | KARGER | |
dc.source | Blood Purification | |
dc.subject | Hematology | |
dc.title | Angiopoietin as a novel prognostic marker in kidney disease | |
dc.type | Journal article | |
dspace.entity.type | Publication | |
local.contributor.kuauthor | Yıldız, Abdullah Burak | |
local.contributor.kuauthor | Çöpür, Sidar | |
local.contributor.kuauthor | Tanrıöver, Cem | |
local.contributor.kuauthor | Yavuz, Furkan | |
local.contributor.kuauthor | Vehbi, Sezan | |
local.contributor.kuauthor | Kanbay, Mehmet |